APA (7th ed.) Citation

A, B., JP, D., N, M., G, L., U, B., & JA, S. (2025). Malignant melanoma and multiple sclerosis therapies: A disproportionality analysis of the FDA adverse event reporting system. Multiple sclerosis (Houndmills, Basingstoke, England), 31(13), 1591. https://doi.org/10.1177/13524585251342725

Chicago Style (17th ed.) Citation

A, Balshi, Dempsey JP, Manning N, Leuenberger G, Baber U, and Sloane JA. "Malignant Melanoma and Multiple Sclerosis Therapies: A Disproportionality Analysis of the FDA Adverse Event Reporting System." Multiple Sclerosis (Houndmills, Basingstoke, England) 31, no. 13 (2025): 1591. https://doi.org/10.1177/13524585251342725.

MLA (9th ed.) Citation

A, Balshi, et al. "Malignant Melanoma and Multiple Sclerosis Therapies: A Disproportionality Analysis of the FDA Adverse Event Reporting System." Multiple Sclerosis (Houndmills, Basingstoke, England), vol. 31, no. 13, 2025, p. 1591, https://doi.org/10.1177/13524585251342725.